Study shows poor likely to forgo needed healthcare due to costs. Medical researchers surveyed patients in Harvard Pilgrim Health Care Inc.’s high-deductible health insurance plans. They wanted to see how people with incomes above 300 percent of poverty and those making far less paid for healthcare up front. Their study published in the Archives of Internal Medicine showed that almost 60 percent of those in the low-income group said they delayed or went without needed care in the previous 6 months due to costs, according to NPR’s Shots health blog.
Report: Patients willing to pay up to $1,000 per year for healthcare. More than 74 percent of insured consumers responding to a survey said they are willing and able to pay out-of-pocket medical expenses of less than $1,000 a year, but many respondents say that a lack of financing options and confusion are problems, according to McKinsey & Company research.
Employers draw health reform line. What would happen if the rank and file of America’s employers, financially overwhelmed by the burden associated with sponsoring health coverage, suddenly opted out? Kaiser Health News asks.
Dr. Reddy’s buys U.S. penicillin plant. GlaxoSmithKline will sell a penicillin manufacturing facility in Bristol, Tennessee, to Dr. Reddy’s Laboratories, one of India’s largest drug makers, according to the News & Observer.
Zogenix shares slide after IPO. Shares of San Diego-based Zogenix (NSDQ:ZGNX) slid to $3.98 a share in the first day of trading Tuesday after the drug-and-device startup substantially revised the terms of its initial public offering, raising less than anticipated, according to Xconomy San Diego.
GM stole the IPO limelight from biotechs. Both Zogenix and Anacor Pharmaceuticals failed to price last week while automaker General Motors stole the headlines with its $20 billion IPO, according to The Burrill Report.
But another IPO is cooking in North Carolina. Meanwhile, Tranzyme, a small Durham, North Carolina, company developing experimental treatments for gastrointestinal diseases, is planning to raise as much as $75 million in an initial public offering of stock, the N&A reports.
Material from MedCity News was used in this report.
